NewGenIvf prices $1.25 million public offering at $0.07 per share
- NewGenIvf Group Limited priced a public offering with gross proceeds of $1.25 million
- The offering price is set at $0.07 per Common Share or $0.06999 per Pre-Funded Warrant
- Proceeds will fund investment in K25.ai, debt restructuring, and working capital needs
- Aegis Capital Corp. acts as the exclusive placement agent for the transaction
*this image is generated using AI for illustrative purposes only.
NewGenIvf Group Limited (NASDAQ: NIVF) announced the pricing of a $1.25 million public offering on a reasonable best efforts basis. The transaction is expected to close on or about September 30, 2026.
The offering comprises 17,857,143 Ordinary Shares or Pre-Funded Warrants in lieu thereof. The public offering price is set at $0.07 per Common Share. For Pre-Funded Warrants, the price is $0.06999, reflecting an exercise price of $0.00001 per warrant. These warrants are immediately exercisable until exercised in full.
Use of Proceeds and Strategic Allocation
The company intends to deploy the net proceeds, combined with existing cash resources, across several strategic initiatives. Key allocations include:
- Investment in K25.ai
- Restructuring of debt securities
- Working capital for manufacturing and deployment of Nodexus machines in the cell-sorting business
- General corporate purposes
| Offering Component | Details |
|---|---|
| Gross Proceeds | $1.25 million |
| Price per Share | $0.07 |
| Price per Warrant | $0.06999 |
| Exercise Price | $0.00001 |
| Total Units | 17,857,143 |
Regulatory and Advisory Details
The offering was conducted under a registration statement on Form F-1 (No. 333-298442), filed with the U.S. Securities and Exchange Commission (SEC) on August 20, 2026, and declared effective on September 28, 2026. Aegis Capital Corp. serves as the exclusive placement agent. Han Kun Law Offices LLP acts as U.S. counsel to the company, while Kaufman & Canoles, P.C. represents Aegis Capital Corp.
What the Numbers Show
The pricing structure highlights a significant reliance on equity dilution to fund operational pivots. With gross proceeds fixed at $1.25 million against a low share price of $0.07, the issuance of over 17.8 million units indicates substantial expansion of the outstanding share count. This capital injection is explicitly directed toward non-core diversification (K25.ai) and liability management (debt restructuring), suggesting a strategic shift to balance immediate financial obligations with long-term technological investments.
How will the substantial equity dilution from issuing 17.8 million shares impact NIVF's existing shareholder value and future capital raising capacity?
What specific milestones or revenue projections has NewGenIvf set for the deployment of Nodexus machines to justify this capital injection?
What are the strategic rationale and expected ROI for investing in K25.ai, given its divergence from the company's core IVF operations?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
